Polymer-drug Conjugates MarketSize and Trends

Polymer-drug Conjugates Market Driver

New pipeline drugs developed using polymer-drug conjugation are expected to propel growth of the polymer-drug conjugates market. For instance, in March 2016, National Cancer Institute (NCI) started undergoing phase II clinical study for CRLX101, a nanoparticle drug conjugate composed of 20(S)-Camptothecin conjugated to a linear, cyclodextrin-polyethylene glycol-based polymer, for the treatment of metastatic prostate cancer and the trial is expected to complete by March 2020.

Polymer-drug Conjugates Market – Regional Analysis

On the basis of region, the global polymer-drug conjugates market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is projected to hold dominant position in the global polymer-drug conjugates market due to increase in number of clinical trials in the U.S. For instance, in January 2018, Apellis Pharmaceuticals announced to conduct phase III clinical study for APL-2 in the U.S. APL-2 is a synthetic cyclic peptide drug conjugated to a polyethylene glycol polymer for the treatment of geographic atrophy associated with age-related macular degeneration.

Furthermore, increasing research on novel Drug Delivery Systems (DDS) in Asia Pacific is expected to contribute to significant growth of the Polymer-drug Conjugates Market in the region during the forecast period. For instance, in August 2018, Osaka University, in collaboration with Tokyo Institute of Technology, Japan, developed a DDS using polyethylene glycol and polylysine block copolymer, with ubenimex conjugate (PEG-b-PLys (Ube). Intravenous injection of ubenimex with these polymers in mice, found to reduce the tumor size significantly. Such results are expected to be a positive traction for growth of the market during the forecast period.

Polymer-drug Conjugates Market – Taxonomy

By Product Type